7ZUC

Human Major Histocompatibility Complex A2 allele presenting LLLGIGILV


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.89 Å
  • R-Value Free: 0.247 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.213 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

Dolton, G.Rius, C.Wall, A.Szomolay, B.Bianchi, V.Galloway, S.A.E.Hasan, M.S.Morin, T.Caillaud, M.E.Thomas, H.L.Theaker, S.Tan, L.R.Fuller, A.Topley, K.Legut, M.Attaf, M.Hopkins, J.R.Behiry, E.Zabkiewicz, J.Alvares, C.Lloyd, A.Rogers, A.Henley, P.Fegan, C.Ottmann, O.Man, S.Crowther, M.D.Donia, M.Svane, I.M.Cole, D.K.Brown, P.E.Rizkallah, P.Sewell, A.K.

(2023) Cell 186: 3333-3349.e27

  • DOI: https://doi.org/10.1016/j.cell.2023.06.020
  • Primary Citation of Related Structures:  
    7Q98, 7Q99, 7Q9A, 7Q9B, 7ZUC

  • PubMed Abstract: 

    The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A 02:01-restricted epitopes EAAGIGILTV, LLLGIGILVL, and NLSALGIFST from Melan A, BST2, and IMP2, respectively. Atomic structures of a TCR bound to all three antigens revealed the importance of the shared x-x-x-A/G-I/L-G-I-x-x-x recognition motif. Multi-epitope targeting allows individual T cells to attack cancer in several ways simultaneously. Such "multipronged" T cells exhibited superior recognition of cancer cells compared with conventional T cell recognition of individual epitopes, making them attractive candidates for the development of future immunotherapies.


  • Organizational Affiliation

    Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
MHC class I antigen
A, D
276Homo sapiensMutation(s): 0 
Gene Names: HLA-A
UniProt
Find proteins for O78126 (Homo sapiens)
Explore O78126 
Go to UniProtKB:  O78126
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO78126
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
Beta-2-microglobulin
B, E
100Homo sapiensMutation(s): 0 
Gene Names: B2MCDABP0092HDCMA22P
UniProt & NIH Common Fund Data Resources
Find proteins for P61769 (Homo sapiens)
Explore P61769 
Go to UniProtKB:  P61769
PHAROS:  P61769
GTEx:  ENSG00000166710 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP61769
Sequence Annotations
Expand
  • Reference Sequence

Find similar proteins by:  Sequence   |   3D Structure  

Entity ID: 3
MoleculeChains Sequence LengthOrganismDetailsImage
LEU-LEU-LEU-GLY-ILE-GLY-ILE-LEU-VAL
C, F
9Homo sapiensMutation(s): 0 
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.89 Å
  • R-Value Free: 0.247 
  • R-Value Work: 0.212 
  • R-Value Observed: 0.213 
  • Space Group: P 32 1 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 85.259α = 90
b = 85.259β = 90
c = 213.486γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
PHASERphasing
PDB_EXTRACTdata extraction
DIALSdata scaling

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2023-05-24
    Type: Initial release
  • Version 1.1: 2023-09-06
    Changes: Data collection, Database references, Refinement description
  • Version 1.2: 2024-02-07
    Changes: Refinement description
  • Version 1.3: 2024-11-06
    Changes: Structure summary